Natco Pharma Downgraded to Sell Amidst Weak Financials and Bearish Technicals

Financial Performance Deteriorates Sharply

The primary catalyst for the downgrade lies in Natco Pharma’s recent financial results for the quarter ended December 2025. The company reported a significant decline in key metrics compared to its previous four-quarter averages. Net sales plummeted by 41.0% to ₹647.30 crores, while profit before tax excluding other income (PBT less OI) dropped by a staggering 71.6% to ₹103.00 crores. Net profit after tax (PAT) also fell sharply by 60.6% to ₹151.50 crores.

These figures have dragged the company’s financial trend score from a neutral 1 to a negative -15 over the last three months, signalling a clear downturn. Return on capital employed (ROCE) for the half-year period hit a low of 21.17%, and the debtors turnover ratio also declined to 2.55 times, indicating slower collections and operational inefficiencies.

On a positive note, Natco Pharma’s cash and cash equivalents stood at a robust ₹2,690.20 crores for the half-year, the highest recorded, providing some liquidity cushion amid the downturn. However, non-operating income accounted for 36.06% of PBT, suggesting that core business profitability is under pressure.

Valuation and Market Performance

Despite the financial setbacks, Natco Pharma maintains an attractive valuation profile. The company’s return on equity (ROE) remains healthy at 16.25%, with a low average debt-to-equity ratio of zero, underscoring prudent financial management. The stock trades at a price-to-book value of 1.7, which is considered fair relative to its peers’ historical valuations.

However, the stock’s market performance has been disappointing. Over the past year, Natco Pharma’s share price has declined by 15.54%, significantly underperforming the BSE500 index, which gained 11.06% during the same period. This underperformance is compounded by a year-to-date return of -9.01%, compared to the Sensex’s -3.04%.

Longer-term returns present a mixed picture: while the stock has delivered a 53.95% gain over three years, it lags the Sensex’s 60.30% return over five years and the Sensex’s 259.46% over ten years. This uneven performance reflects volatility and challenges in sustaining growth momentum.

Technical Indicators Turn Bearish

Technical analysis of Natco Pharma’s stock price reveals a shift from mildly bullish to bearish trends. Key momentum indicators such as the Moving Average Convergence Divergence (MACD) are bearish on both weekly and monthly charts. Bollinger Bands also signal bearishness across these timeframes, while daily moving averages confirm downward pressure.

The Relative Strength Index (RSI) presents a mixed signal: neutral on the weekly chart but bullish on the monthly, suggesting some underlying strength over the longer term. However, the Know Sure Thing (KST) indicator is bullish weekly but bearish monthly, reflecting short-term volatility against longer-term weakness.

Volume-based indicators like On-Balance Volume (OBV) are mildly bearish weekly, indicating selling pressure. Dow Theory trends show no clear direction on weekly or monthly scales, adding to the uncertainty.

These technical signals, combined with the recent price decline of 2.12% on 16 February 2026 to ₹822.10 from a previous close of ₹839.90, reinforce the cautious stance adopted by analysts.

Quality Assessment and Institutional Confidence

Despite the downgrade, Natco Pharma retains some quality attributes. The company boasts a high management efficiency reflected in its ROE of 16.25%, indicating effective utilisation of shareholder capital. Its low debt-to-equity ratio of zero further highlights conservative financial leverage, reducing risk exposure.

Institutional investors hold a significant 20.55% stake in the company, and this share has increased by 0.59% over the previous quarter. Such holdings typically indicate confidence from sophisticated investors who have the resources to analyse fundamentals thoroughly.

Nonetheless, the deteriorating financial trend and bearish technical outlook have outweighed these positives, prompting the MarketsMOJO grading system to downgrade Natco Pharma’s Mojo Grade from Hold to Sell, with a current Mojo Score of 36.0.

Outlook and Investor Considerations

Natco Pharma’s downgrade to Sell reflects a convergence of negative financial trends and bearish technical signals, despite some underlying strengths in valuation and management quality. The sharp decline in quarterly sales and profits raises concerns about near-term operational challenges, while the technical indicators suggest limited upside momentum in the stock price.

Investors should weigh these factors carefully, especially given the stock’s underperformance relative to broader market indices over the past year. While the company’s strong cash position and low leverage provide some buffer, the significant drop in profitability and sales cannot be overlooked.

For those currently holding Natco Pharma shares, it may be prudent to reassess portfolio allocations in light of these developments. Conversely, potential investors might consider waiting for clearer signs of financial recovery and technical stabilisation before committing capital.

MarketsMOJO’s comprehensive analysis, incorporating quality, valuation, financial trend, and technical parameters, offers a holistic view that supports the current Sell rating. This downgrade serves as a cautionary signal amid a volatile sector and challenging macroeconomic backdrop.

Summary of Key Metrics

• Mojo Score: 36.0 (Sell, downgraded from Hold)
• Market Cap Grade: 3
• Net Sales (Q3 FY25-26): ₹647.30 crores (-41.0%)
• PBT less OI (Q3 FY25-26): ₹103.00 crores (-71.6%)
• PAT (Q3 FY25-26): ₹151.50 crores (-60.6%)
• ROCE (HY): 21.17% (lowest)
• Debtors Turnover Ratio (HY): 2.55 times (lowest)
• Cash & Cash Equivalents (HY): ₹2,690.20 crores (highest)
• ROE: 16.25%
• Debt to Equity: 0 (average)
• Price to Book Value: 1.7
• Institutional Holdings: 20.55% (up 0.59% QoQ)
• Current Price (16 Feb 2026): ₹822.10
• 52-Week Range: ₹660.05 – ₹1,242.45

Comparative Returns vs Sensex

• 1 Week: Natco Pharma -0.14%, Sensex -1.14%
• 1 Month: Natco Pharma -5.45%, Sensex -1.20%
• Year-to-Date: Natco Pharma -9.01%, Sensex -3.04%
• 1 Year: Natco Pharma -15.54%, Sensex +8.52%
• 3 Years: Natco Pharma +53.95%, Sensex +36.73%
• 5 Years: Natco Pharma -3.79%, Sensex +60.30%
• 10 Years: Natco Pharma +81.10%, Sensex +259.46%

Conclusion

Natco Pharma Ltd.’s recent downgrade to a Sell rating by MarketsMOJO is a reflection of its deteriorating financial health and bearish technical outlook, despite some valuation appeal and strong management efficiency. Investors should approach the stock with caution, monitoring upcoming quarterly results and technical developments closely before making investment decisions.

Unlock special upgrade rates for a limited period. Start Saving Now →